Valuation: Insmed Incorporated

Market Cap 23.2B 20.33B 18.79B 17.28B 32.61B 2,237B 33.14B 225B 88.09B 1,094B 87.1B 85.2B 3,771B P/E 2026 *
-42x
P/E 2027 * 210x
Enterprise Value 22.63B 19.84B 18.34B 16.86B 31.82B 2,182B 32.33B 219B 85.94B 1,068B 84.98B 83.13B 3,679B EV / Sales 2026 *
13.3x
EV / Sales 2027 * 8.02x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-1.20%
1 week-1.94%
Current month+0.38%
1 month+11.71%
3 months-25.07%
6 months-34.55%
Current year-38.51%
1 week 105.07
Extreme 105.07
111.6
1 month 95.27
Extreme 95.27
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
6/25/26 Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-1.94%+4.35%+402.68% 23.48B
+0.21%-0.79%+53.17%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
+0.74%+2.32%-16.23%-14.44% 23.13B
+3.46%+2.52%+34.01%-5.41% 19.36B
-1.18%-2.97%+30.12%-33.30% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%0.00%+29.70%+643.91% 14.83B
-0.70%-0.91%+24.87%+179.47% 14.06B
-3.21%+0.88%+60.32%+151.29% 12.76B
Average +0.54%-1.42%+43.46%+174.93% 24.63B
Weighted average by Cap. +1.23%-1.54%+42.44%+138.75%

Financials

2026 *2027 *
Net sales 1.7B 1.49B 1.38B 1.26B 2.39B 164B 2.42B 16.44B 6.45B 80.09B 6.37B 6.23B 276B 2.77B 2.43B 2.24B 2.06B 3.9B 267B 3.96B 26.84B 10.52B 131B 10.4B 10.18B 450B
Net income -560M -491M -454M -418M -788M -54.04B -801M -5.43B -2.13B -26.44B -2.1B -2.06B -91.1B 70.56M 61.85M 57.17M 52.58M 99.2M 6.8B 101M 684M 268M 3.33B 265M 259M 11.47B
Net Debt -566M -496M -458M -421M -795M -54.53B -808M -5.48B -2.15B -26.68B -2.12B -2.08B -91.93B -983M -862M -797M -733M -1.38B -94.8B -1.4B -9.52B -3.73B -46.39B -3.69B -3.61B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-20 US$107.02 -1.20% 2,015,922
26-07-17 US$108.32 +0.80% 2,002,884
26-07-16 US$107.46 -2.14% 2,754,212
26-07-15 US$109.81 -0.27% 2,116,813
26-07-14 US$110.11 +0.89% 1,848,330
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
107.02USD
Average target price
196.38USD
Spread / Average Target
+83.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock